Europe Epilepsy Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Epilepsy Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Epilepsy Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Epilepsy Market Regional Analysis

6.2 Europe Epilepsy Market Revenue 2020-2030 (US$ Million)

6.3 Europe Epilepsy Market Forecast Analysis

7. Europe Epilepsy Market Analysis – by Type

7.1 Progressive Myoclonic Epilepsy

7.1.1 Overview
7.1.2 Progressive Myoclonic Epilepsy: Europe Epilepsy Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.2 Reflex Epilepsy

7.2.1 Overview
7.2.2 Reflex Epilepsy: Europe Epilepsy Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.3 Generalized Epilepsy

7.3.1 Overview
7.3.2 Generalized Epilepsy: Europe Epilepsy Market – Revenue and Forecast, 2020-2030 (US$ Million)

8. Europe Epilepsy Market Analysis – by Route of Administration

8.1 Oral

8.1.1 Overview
8.1.2 Oral: Europe Epilepsy Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.2 Parenteral

8.2.1 Overview
8.2.2 Parenteral: Europe Epilepsy Market – Revenue and Forecast, 2020-2030 (US$ Million)

9. Europe Epilepsy Market Analysis – by Age Group

9.1 Adult and Children

9.1.1 Overview
9.1.2 Adult and Children: Europe Epilepsy Market – Revenue and Forecast, 2020-2030 (US$ Million)

10. Europe Epilepsy Market – Europe Analysis

10.1 Overview

10.2 Europe

10.2.1 Europe Epilepsy Market Breakdown, by Key Country, 2023 and 2030 (%)
10.2.1.1 Europe Epilepsy Market – Revenue and Forecast Analysis – by Country
10.2.1.1 UK: Europe Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.1.1 UK: Europe Epilepsy Market Breakdown, by Type
10.2.1.1.2 UK: Europe Epilepsy Market Breakdown, by Route of Administration
10.2.1.1.3 UK: Europe Epilepsy Market Breakdown, by Age Group

10.2.1.2 Germany: Europe Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.2.1 Germany: Europe Epilepsy Market Breakdown, by Type
10.2.1.2.2 Germany: Europe Epilepsy Market Breakdown, by Route of Administration
10.2.1.2.3 Germany: Europe Epilepsy Market Breakdown, by Age Group

10.2.1.3 France: Europe Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.3.1 France: Europe Epilepsy Market Breakdown, by Type
10.2.1.3.2 France: Europe Epilepsy Market Breakdown, by Route of Administration
10.2.1.3.3 France: Europe Epilepsy Market Breakdown, by Age Group

10.2.1.4 Russia: Europe Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.4.1 Russia: Europe Epilepsy Market Breakdown, by Type
10.2.1.4.2 Russia: Europe Epilepsy Market Breakdown, by Route of Administration
10.2.1.4.3 Russia: Europe Epilepsy Market Breakdown, by Age Group

10.2.1.5 Italy: Europe Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.5.1 Italy: Europe Epilepsy Market Breakdown, by Type
10.2.1.5.2 Italy: Europe Epilepsy Market Breakdown, by Route of Administration
10.2.1.5.3 Italy: Europe Epilepsy Market Breakdown, by Age Group

10.2.1.6 Rest of Europe: Europe Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.6.1 Rest of Europe: Europe Epilepsy Market Breakdown, by Type
10.2.1.6.2 Rest of Europe: Europe Epilepsy Market Breakdown, by Route of Administration
10.2.1.6.3 Rest of Europe: Europe Epilepsy Market Breakdown, by Age Group

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Abbott Laboratories

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Pfizer Inc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Eisai Co Ltd

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 UCB SA

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 CombiGene AB

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 LivaNova Plc

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Novartis AG

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Medtronic Plc

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 GSK Plc

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 H. Lundbeck AS

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

Europe Epilepsy Market